Valeo Pharma (TSE:VPH) Trading Down 14.3%

Valeo Pharma Inc. (TSE:VPH) traded down 14.3% on Wednesday . The company traded as low as C$0.06 and last traded at C$0.09. 127,381 shares were traded during trading, an increase of 133% from the average session volume of 54,677 shares. The stock had previously closed at C$0.11.

Valeo Pharma Stock Up 11.8 %

The stock has a 50-day simple moving average of C$0.17 and a two-hundred day simple moving average of C$0.19. The firm has a market cap of C$9.37 million, a PE ratio of -0.30 and a beta of 2.56.

Valeo Pharma (TSE:VPH) last announced its quarterly earnings data on Thursday, March 14th. The company reported C($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of C($0.08). The company had revenue of C$13.54 million for the quarter, compared to the consensus estimate of C$15.30 million.

Valeo Pharma Company Profile

Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.